The FDA has announced a draft guidance, titled “Refuse to File: NDA and BLA Submissions to CDER.” The guidance is intended to clarify the circumstances where the CDER (Center for Drug Evaluation and Research) may refuse to file a submitted NDA or BLA, and it reinforces the importance of submitting a complete application. The FDA notes that over the years, determining whether an application is complete has become increasingly more complex; this guidance aims to alleviate this issue and to restore efficiency to the approval process.
The guidance focuses on the FDA’s policy for refusing to file an NDA or a BLA because it is incomplete or is missing required information. Complex, significant deficiencies in an application may result in a refusal to file. These include inadequately organized applications or materially lacking applications; applications containing inadequate information for one or more indications, when multiple indications are submitted in the same application; applications relying on a single trial to demonstrate effectiveness, if the FDA has determined that more than one trial is necessary; applications lacking studies related to the potential abuse of a drug; and a failure to submit data electronically when the FDA has mandated electronic submission.
Comments and suggestions on the draft guidance can be submitted here.
The post FDA Releases New “Refuse to File” Guidance appeared first on Goodwin Procter BioSimilars Blog.